Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2026-03-20 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai SAILUN Biotechnology Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board's approval, the amount involved (up to 500 million RMB), the types of investment products allowed, risk control measures, and the compliance with regulatory rules. The document is a formal disclosure about the company's financing fund management activities, not a full financial report or audit. It does not contain financial statements or detailed financial results but rather an update on capital usage and compliance. The document length is about 3,196 characters, which is relatively short and focused on a specific financing update. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-03-20 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司使用自有资金支付募投项目人员费用并以募集资金等额置换的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (方正证券承销保荐有限责任公司) regarding the use of self-owned funds by Shanghai Sailun Biotechnology Co., Ltd. to pay personnel expenses for fundraising projects and the subsequent replacement with raised funds. It references regulatory rules about fundraising management, approval by the board of directors, and compliance with securities regulations. The document is not a full financial report but a regulatory compliance and verification statement related to fundraising activities. It does not contain financial statements or earnings data, nor is it a brief announcement or a presentation. Given the nature of the document as a regulatory compliance verification and sponsor opinion, it fits best under Regulatory Filings (RNS). The document length is 3260 characters, which is relatively short and consistent with a regulatory filing rather than a full report.
2026-03-20 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from the underwriting and sponsorship institution (方正证券承销保荐有限责任公司) regarding the use of temporarily idle raised funds by Shanghai Sailun Biotechnology Co., Ltd. It includes specifics about the amount of funds raised, their intended use, the cash management plan for idle funds, risk assessments, board approval, and the sponsor's verification opinion. The document references regulatory rules related to raised funds and cash management but does not present financial statements or earnings data. It is not an announcement of a report but a formal verification opinion on the use of raised funds for cash management. This fits the definition of an Audit Report / Information (AR), as it is a standalone audit/verification report related to regulatory compliance and fund usage, not a full annual or interim report, nor a simple announcement or certification. The document length (3257 characters) and content confirm it is a substantive report rather than a brief announcement or certification. Q1 2026
2026-03-20 Chinese
赛伦生物：关于使用自有资金支付募投项目人员费用并以募集资金等额置换的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanghai SAILUN Biotechnology Co., Ltd. regarding the use of self-owned funds to pay personnel expenses for fundraising investment projects and the subsequent replacement with equivalent fundraising funds. It details the board meeting resolution, regulatory compliance, fundraising project details, and the operational process for fund replacement. The document is a formal disclosure about a financing and capital management activity related to the company's fundraising projects, not a full financial report or earnings release. It does not contain financial statements or quarterly/yearly results but focuses on capital usage and replacement procedures. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3055 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is CAP with high confidence.
2026-03-20 Chinese
赛伦生物：2025年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025年度业绩快报公告" which translates to "2025 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2025, including revenue, profit, net income, and other financial metrics. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be disclosed in the company's 2025 Annual Report. The document is relatively short (1799 characters) and serves as a quick earnings update rather than a full comprehensive report. It does not contain full financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a simple announcement of report publication but a brief financial performance summary. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2025
2026-02-26 Chinese
赛伦生物：关于变更签字注册会计师的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from Shanghai SAILUN Biotechnology Co., Ltd. regarding the change of the signing certified public accountant for the 2025 annual audit. It details the replacement of one signing CPA with another, including their qualifications, independence, and impact on the audit work. The document does not contain any financial statements or audit results itself, but rather informs about a personnel change related to the audit. It is not the audit report itself, nor an annual report or interim report. The document is a regulatory announcement about audit personnel changes, fitting best under Audit Report / Information (AR) category, which includes standalone audit reports and related audit information excluding full annual reports. The document length is short and focused on audit personnel change, not a report publication announcement or certification letter. Therefore, the classification is AR with high confidence. FY 2025
2025-12-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.